ArticleActa scientific neurology2024
Hypothesizing Enhanced Brain Activity as A Function of Dopamine Homeostasis as Observed with KB220 in A Male with Delayed Cognitive Performance.
Article in Acta scientific neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-Locus Pro-Dopaminergic Restoration of Reward Brain Circuitry in Reward Deficiency Rescinds Mono-Pharmaceutical Targeting.Neurology (E-Cronicon) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Background: Quantitative electroencephalography (qEEG) has proven invaluable in assessing the neuropsychological impact of various substances, providing insight into their effects on brain activity and cognitive functions. KB220, a nutraceutical neuroadaptogen, has shown promise in modifying the dopaminergic system to enhance cognitive and neurological functions without dependency risks. Case Presentation: A 26-year-old male with a history of multiple neuropsychiatric diagnoses, including ADHD, PTSD, and sensory integration disorder, underwent qEEG analysis to explore the effects of KB220 on brain function. The patient's EEG was recorded before and 60 minutes after oral administration of KB220, observing changes in various frequency bands indicative of cognitive and alertness states. Methods: Baseline and post-administration EEG recordings were analyzed to assess changes in Delta, Theta, Alpha, and Beta wave activities, which correlate with alertness, memory processing, and cognitive engagement. The study utilized a 19-channel EEG with a consistent setup to ensure accurate comparative results. Results: Significant alterations were observed in the patient's EEG post-KB220 administration. There was a notable reduction in Delta activity, suggesting increased alertness. Theta and Alpha activities increased, indicating enhanced working memory and neuronal synchrony. Beta activity changes suggested improved focus and cognitive processing. These shifts point towards restoring dopamine homeostasis, potentially enhancing brain activity and cognitive functions. Conclusion: The case highlights the potential of KB220 to significantly impact brain function and cognitive performance through modulation of the dopaminergic system. These findings support further research into KB220 as a beneficial treatment for cognitive delays and neuropsychiatric conditions beyond traditional applications in addiction and reward deficiency syndrome. The data suggest a broader utility for KB220 in improving cognitive outcomes in patients with complex neuropsychiatric profiles.
Indexed as
Identifiers
41909628PMC13028599What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.